Brenig Therapeutics, Inc. — Form D
Brenig Therapeutics, Inc. of DOVER, DE, a company, filed a Form D exempt-offering notice with the SEC on 2024-07-30. The offering totals $65.0M, of which $30.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-07-30
- Form: D
- Accession: 0002030788-24-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $65.0M
- Amount sold: $30.0M
- Remaining: $35.0M
- Investors: 6
- Date of first sale: 2024-07-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-520099
Issuer
- Name: Brenig Therapeutics, Inc.
- CIK: 0002030788
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 8 THE GREEN, SUITE 8235, DOVER, DE, 19901
- Phone: 818-326-9933
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Michele Cucullu | Director | Dover, DE |
| Iain Dukes | Director | Cambridge, MA |
| Keno Gutierrez | Director | Dover, DE |
| Edward Mathers | Director | South San Francisco, CA |
| Nikolay Savchuk | Director | Dover, DE |
| Iain Dukes | Executive Officer | Cambridge, MA |
| Nikolay Savchuk | Executive Officer | Dover, DE |
More